Given the prevalent use of immune checkpoint inhibitors (ipilimumab, pembrolizumab, nivolumab etc), there will be more demands for PD-L1 testing.

At GPS Ltd, we’re committed to being at the forefront of clinical diagnostics.  We’ve added mismatch repair (MMR) immunohistochemistry testing and offer